Delivery Order SPE2DB22D1106-SPE2DB25FEKC4
Award Date 4/23/25
Potential Completion Date 4/24/25
Potential Value $8.2K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $6,123.36 to AmerisourceBergen Drug Corp for the supply of Actemra 400 mg/20 ml vials on May 27, 2025, with an ultimate completion date of May 28, 2025. This firm fixed-price delivery order, which was competitively awarded without set-aside restrictions, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX) valued at $999.99 billion and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 3, 2025, for the supply of Actemra 400 mg/20 ml vials with a ceiling value of $3,297.92. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of June 4, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a small-value transaction within the company's broader pharmaceutical supply...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Actemra 400 mg/20 mL vials. This competitively awarded, firm fixed-price delivery order has a ceiling value of $7,109.81 and an ultimate completion date of July 30, 2025. The contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Actemra (tocilizumab) is a biologic immunosuppressant...
- The Defense Logistics Agency (DLA) awarded a $13,171.30 delivery order to AmerisourceBergen Drug Corp for 4,568,832,740 units of Actemra 400 mg/20 mL vials on July 18, 2025, with an ultimate completion date of July 21, 2025. This is a firm fixed-price, non-set-aside contract with place of performance in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued...
- The Defense Logistics Agency awarded a $3,297.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ACTEMRA 400 mg/20 ml vials on June 26, 2025, with an ultimate completion date of June 27, 2025. This non-set-aside contract represents a pharmaceutical supply delivery under the company's larger indefinite delivery contract vehicle with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a $3,729.39 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Actemra 200 mg/10 mL vials. The contract, which is a firm fixed price delivery order with an ultimate completion date of August 20, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). This award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,471.52 to AmerisourceBergen Drug Corp for the supply of Actemra 200 mg/10 mL vials on July 3, 2025, with a completion date of July 7, 2025. This firm fixed-price, non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a potential value of $1 billion through December 2026. The place of performance...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of ACTEMRA 162 mg/0.9 mL syringes, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions. This firm fixed-price delivery order, valued at $13,755.85, represents a competitive award with no set-aside designation and is scheduled for completion by September 18, 2025. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Actemra 162 mg/0.9 mL syringes with a ceiling value of $16,453.58. This is a firm fixed-price delivery order with an ultimate completion date of September 11, 2025, and no set-aside designation was used in the award. The product will be delivered to the company's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a $15,029.42 delivery order to AmerisourceBergen Drug Corp for Actemra 400 mg/20 ml vials on June 5, 2025, with an ultimate completion date of June 6, 2025. This non-set-aside, firm fixed price contract represents a single delivery order for a pharmaceutical product to be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award falls under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical...